Tert-Butyl (2S)-2-(Aminomethyl)Pyrrolidine-1-Carboxylate

When the (S)-configured aminomethylpyrrolidine scaffold is integrated into a JAK1-selective inhibitor targeting atopic dermatitis, the downstream crystallisation behaviour and polymorph consistency of the final active pharmaceutical ingredient become acutely dependent on the enantiomeric purity of the intermediate. Tert‑Butyl (2S)-2‑(aminomethyl)pyrrolidine‑1‑carboxylate is introduced as a chirally pure building block in the penultimate amide‑bond‑forming step, where the free amine — generated immediately prior to coupling via controlled HCl‑mediated deprotection — reacts with a pre‑activated heteroaryl carboxylic acid. The reaction stoichiometry is clamped at 1.00–1.05 equivalents of the pyrrolidine‑derived amine relative to the acid coupling partner, with the molar excess minimised to suppress bis‑alkylation and to simplify the subsequent aqueous work‑up. Process‑scale manufacturing under ICH Q7 section 12 mandates rigid starting‑material specifications: the intermediate is typically released only when the chemical purity determined by reversed‑phase HPLC (UV detection at 210 nm) exceeds 99.0 area% and the enantiomeric excess measured by chiral HPLC (Chiralpak AD‑H column, 250 × 4.6 mm, n‑hexane/ethanol 90:10 v/v) is not less than 99.5%. Residual solvents are controlled to meet ICH Q3C Option 2 concentrations; specific limits for tert‑butanol (5000 ppm as a Class 3 solvent), dichloromethane (600 ppm, Class 2), and N,N‑dimethylformamide (880 ppm, Class 2) are verified by headspace GC‑FID before the container is released to the GMP coupling suite. The downstream transformation proceeds in a jacketed 2000 L glass‑lined reactor equipped with a retreat‑curve impeller and a HASTELLOY C‑22 temperature probe, where the pre‑formed active ester — generated from the carboxylic acid fragment using 1.05–1.10 eq of EDCI·HCl and 1.15 eq of HOBt monohydrate in anhydrous dichloromethane — is combined with the freshly liberated (S)‑2‑(aminomethyl)pyrrolidine freebase at −10 to −5 °C. After 16–20 h of low‑temperature stirring, the batch is warmed to 20 °C, washed with saturated sodium bicarbonate and brine, and concentrated under vacuum (≤ 45 °C jacket). The crude amide is then subjected to a final Boc‑deprotection using 4.0 M HCl in 1,4‑dioxane (3.5–4.0 eq HCl) at 0–5 °C, neutralised with aqueous sodium hydroxide, and the free base is crystallised as the phosphate salt from isopropanol/water (85:15) to yield the API monophosphate monohydrate, a potent, ATP‑competitive JAK1 inhibitor indicated for moderate‑to‑severe atopic dermatitis.

Under What Process Conditions Does Epimerization Exceed 0.5% During N‑Boc Cleavage?

Epimerization of the stereogenic centre at the pyrrolidine C‑2 position during N‑Boc deprotection is the single largest determinant of yield loss and purification burden in multi‑kilogram campaigns, and the threshold at which chiral purity becomes commercially irrecoverable is remarkably narrow. When trifluoroacetic acid (TFA) is employed neat or as a 50% v/v solution in dichloromethane, the half‑life of the Boc group at 20 °C is typically below 30 minutes, yet the rate of proton abstraction at C‑2 accelerates sharply once the local temperature exceeds 8 °C. Empirical calorimetry data collected on a Mettler‑Toledo RC1e reaction calorimeter during the development of a DPP‑4 inhibitor intermediate indicate that the heat of deprotection (ΔH) approaches −120 kJ/mol, and if the jacket set‑point is not adjusted to compensate for the exotherm during the initial 30% of the TFA addition, the internal temperature overshoots into the 15–20 °C band, where epimerization levels of 0.8–1.2% are consistently observed. This is not reversible by recrystallisation because the diastereomeric impurity, in this specific scaffold, has a solubility nearly identical to the desired enantiomer in the standard isopropanol/n‑heptane solvent system. Consequently, the operating window is locked at −5 to +5 °C throughout the entire TFA charging period, which at 500 kg scale requires a jacket filled with silicone oil maintained at −25 °C and a PTFE‑lined multi‑stage turbine agitator running at 85–95 rpm to ensure sufficient radial mixing. An alternative cleavage protocol that substitutes TFA with anhydrous HCl gas in 1,4‑dioxane (4.0–4.5 eq HCl) reduces the thermal hazard but introduces a competing ring‑opening side reaction if residual water exceeds 0.05 wt%; therefore the dioxane is pre‑dried over activated 3 Å molecular sieves to a Karl Fischer titre of ≤ 100 ppm. Under these strictly anhydrous, low‑temperature conditions, the deprotected (S)‑2‑(aminomethyl)pyrrolidine dihydrochloride is obtained with 99.8% ee and 97% chemical purity (non‑volatile residue basis), directly from filtration without column chromatography. The lot is then accepted for the next coupling step only when the chiral purity meets the specification of ≥ 99.7% ee set by the downstream manufacturing site’s compliance with ICH Q7 section 11 and the technical requirements of the API’s Drug Master File. Residual fluoride ion from TFA‑based deprotection is controlled to ≤ 10 ppm (ion‑selective electrode method) since fluoride interferes with palladium‑catalysed hydrogenation planned later in the synthesis; this limit aligns with the general heavy metal and impurity controls of ICH Q3D. The tablet formulation that ultimately incorporates the DPP‑4 inhibitor, a once‑weekly oral antihyperglycaemic agent for type 2 diabetes mellitus, imposes its own layer of process stringency: any pyrrolidine‑related substance exceeding 0.10% by HPLC must be identified per ICH Q3A(R2) and toxicologically qualified, a workflow that makes the upstream epimerization control not a quality target but a commercial necessity.

In the heterogeneous continuous‑flow approach adopted by one contract development and manufacturing organisation as a fallback when vessel utilisation reaches a bottleneck, the Boc‑protected pyrrolidine dissolved in acetonitrile (0.8 M) is passed through a fixed‑bed reactor packed with sulfonic acid‑functionalised silica (particle size 150–250 µm, bed volume 50 mL) at a residence time of 90 seconds. The back‑pressure regulator is set at 3.5 bar to prevent vapour lock, and the column jacket is circulated with a −10 °C coolant. Under these conditions the epimerization remains below 0.2% for runs lasting 8 hours, after which the silica activity declines and the Boc‑cleavage conversion drops below 98%, triggering a pre‑programmed divert valve. The manufacturer targeting a weekly DPP‑4 inhibitor capsule, administered at 25 mg and 100 mg strengths, demands a supply chain capable of delivering the deprotected amine with a process capability index Cpk ≥ 1.33 for enantiomeric purity, a requirement that directly informs the choice of deprotection chemistry at the intermediate supplier level.

Chiral Amine Loading on Trityl Chloride Resin for Solid‑Phase Peptide Mimetics

Attachment of orthogonally protected chiral amines to solid supports constitutes a specialised downstream niche where this pyrrolidine derivative functions not as a transient intermediate but as a position‑specific modifier of peptide backbone conformation. In the preparation of β‑turn mimetics that incorporate a pyrrolidine‑derived staple, the Boc‑protected (S)‑2‑(aminomethyl)pyrrolidine is coupled to a 2‑chlorotrityl chloride resin (loading 1.0–1.6 mmol/g) in anhydrous dichloromethane in the presence of 4.0 equiv of N,N‑diisopropylethylamine. The addition ratio of the amine hydrochloric salt to resin is adjusted to 0.95 eq relative to the active chloride sites to ensure that residual free chloride is available for end‑capping with methanol, thereby preventing deletion sequences in the subsequent Fmoc‑based peptide elongation. The final substitution level, quantified by Fmoc release from the next amino acid attached, typically falls in the range 0.55–0.80 mmol/g, a value that is critically dependent on the swelling volume of the resin in N‑methyl‑2‑pyrrolidone (NMP) and on the exclusion of moisture, which hydrolyses the trityl chloride faster than the amine nucleophile. Compliance with ICH Q7 during the preparation of the pre‑loaded resin for GMP peptide API synthesis mandates that the residual solvents and reagents — particularly dichloromethane (≤ 600 ppm, ICH Q3C Class 2), N,N‑diisopropylethylamine, and methanol — be reduced in a vacuum oven (≤ 35 °C, 10 mbar) for a minimum of 12 h, with the drying endpoint confirmed by thermogravimetric analysis showing weight loss below 0.5% at 105 °C. The resin‑bound pyrrolidine construct then undergoes iterative Fmoc deprotection with 20% piperidine in DMF, followed by acylation with Fmoc‑protected amino acids using HBTU/0.5 M DIEA, to forge a macrocyclic heptapeptide analogue that displays an IC₅₀ value in the nanomolar range against the integrin αvβ3 receptor in a competitive ELISA with immobilised vitronectin. The resulting lyophilised peptide acetate is released from the resin using a cleavage cocktail of TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v) at 20 °C for 2 h; the crude peptide is precipitated in cold methyl tert‑butyl ether and purified by preparative reversed‑phase HPLC on a C18 column (250 × 50 mm, 10 µm) with a gradient of acetonitrile in 0.1% aqueous TFA. The purified cyclopeptide acetate, designated as a parenteral integrin antagonist for the treatment of diabetic macular oedema, must not contain more than 0.05% of the uncyclised linear precursor and must meet the bacterial endotoxin limit of ≤ 0.5 EU/mg per Ph.Eur. 2.6.14, a criterion that places rigorous demands on the initial resin‑loading consistency and the absence of leaching during the elongation cycles.

If the downstream coupling requires the anhydrous freebase of (S)‑2‑(aminomethyl)pyrrolidine because the electrophile is an acid‑sensitive chloroformate or an activated carbamoyl chloride, the isolation strategy diverges substantially from the direct salt formation normally practised in bulk API sequences. The freebase is generated in a biphasic system by suspending the dihydrochloride salt in dichloromethane and adding 30% w/w aqueous sodium hydroxide to pH > 12 at 0–5 °C, then separating the organic layer and drying it over anhydrous sodium sulfate for 2 h. Filtration yields a clear, colourless solution that must be concentrated under reduced pressure (≤ 30 °C, 150 mbar) because the free amine begins to absorb atmospheric carbon dioxide within minutes, forming a carbamate that drastically lowers the nucleophilicity. In a production campaign for a heterobifunctional PROTAC molecule intended for an oral androgen receptor degrader, the freshly prepared freebase was reacted with a degassed solution of the Von Hippel‑Lindau E3 ligase ligand‑conjugated carboxylate in tetrahydrofuran, using 1.0 eq of the freebase and 1.02 eq of the pre‑activated mixed anhydride formed from isobutyl chloroformate and N‑methylmorpholine at −15 °C. The coupling was complete within 40 min, as judged by in‑process HPLC, and the amide product was isolated by precipitation into ice‑cold water, filtration, and slurry‑washing with methyl tert‑butyl ether. Residual free amine in the isolated solid was quantified by a pre‑column derivatisation HPLC method using 2,4‑dinitrofluorobenzene; the specification of ≤ 0.10% w/w free amine was met after 3 slurry cycles. Throughout this operation, the vessel atmosphere was maintained under nitrogen with a relative humidity of ≤ 30%, as the amide product exhibits hygroscopicity that induces degradation via a cyclic imide pathway when the water content exceeds 0.3%. The PROTAC conjugate subsequently progresses to a lipid nanoparticle formulation for subcutaneous administration, and the clinical batch records require that the total aerobic microbial count (TAMC) of the intermediate be below 100 CFU/g and that residual palladium from an earlier Sonogashira step be controlled to ≤ 5 ppm, in accordance with ICH Q3D Option 2B for parenteral products. The resulting product is a bivalent degrader molecule that recruits the CRBN E3 ubiquitin ligase to the androgen receptor, achieving a DC₅₀ of 3 nM in LNCaP cell lines.

From Late‑Stage Chan–Lam Coupling to KRAS G12D Inhibitor Backbones

When the pyrrolidine nitrogen itself becomes the nucleophilic partner in a copper‑catalysed aryl amination, the Boc‑protected amine form offers a direct, protecting‑group‑compatible route into highly decorated bi‑aryl pharmacophores typical of the tetrahydropyridopyrimidine class of KRAS G12D inhibitors. The Chan–Lam coupling of Tert‑Butyl (2S)‑2‑(aminomethyl)pyrrolidine‑1‑carboxylate with a pre‑functionalised arylboronic acid pinacol ester is conducted at 30–40 °C in an oxygen‑enriched atmosphere (5% O₂ in nitrogen, achieved by mass flow controllers) using copper(I) iodide (0.15 eq) as the catalyst and pyridine (1.5 eq) as the ligand in dichloromethane. The addition stoichiometry is carefully balanced: the boronic ester is used at 1.20 eq relative to the pyrrolidine, but the excess is subsequently scavenged on a silica‑bound diol resin cartridge to prevent copper‑boron adduct carryover into the next Miyaura borylation step. Process analytical technology (PAT) in the form of an in‑situ ReactIR 15 probe monitoring the disappearance of the pyrrolidine N–H stretch at 3320–3340 cm⁻¹ triggers the quench with aqueous ammonium chloride (15% w/v) after 16–20 h. The organic phase is then washed with 10% w/v aqueous ammonia to reduce residual copper to ≤ 25 ppm before being subjected to solvent exchange into toluene for the subsequent Suzuki–Miyaura cross‑coupling with a chloroheteroarene. The reaction scheme is formally governed by ICH Q11 guidelines on the selection of starting materials and the justification of the regulatory starting material point: because the Chan–Lam adduct retains an intact Boc group and two additional synthetic transformations before the late‑stage salt formation, the manufacturer positions the aryl‑pyrrolidine intermediate as a late regulatory starting material rather than an API intermediate, a classification that demands complete characterisation by ¹H NMR, ¹³C NMR, high‑resolution mass spectrometry, and differential scanning calorimetry (DSC) for polymorph identification, as well as a specification for palladium content below 10 ppm prior to use in the final steps. The terminal API, a highly selective, non‑covalent KRAS G12D inhibitor formulated as an amorphous solid dispersion in a hypromellose acetate succinate (HPMC‑AS) matrix, requires the chiral pyrrolidine subunit to remain configurationally stable throughout the entire sequence, a property that is verified at the intermediate stage by chiral SFC analysis (Chiralpak IG‑3 column, CO₂/methanol 80:20, back‑pressure 150 bar) with a detection limit of 0.05% for the (R)‑enantiomer. The tablet product, intended for once‑daily oral administration in KRAS G12D‑mutated pancreatic adenocarcinoma, is manufactured under the controlled humidity conditions necessitated by the hygroscopic nature of the spray‑dried intermediate; relative humidity above 40% during compression induces phase separation of the drug from the polymer, a failure mode documented during scale‑up from 5 kg to 50 kg batches on a Korsch XL 400 rotary press and addressed by retrofitting the press enclosure with a Munters desiccant dehumidifier delivering air at −40 °C dew point.

A distinct manufacturing pathway that exploits the nucleophilicity of the exocyclic aminomethyl group without deprotecting the Boc‑protected pyrrolidine nitrogen first involves reductive amination with a pyrazole‑4‑carbaldehyde derivative. The aldehyde, substituted at the 1‑position with a 2,2,2‑trifluoroethyl group, is condensed with Tert‑Butyl (2S)‑2‑(aminomethyl)pyrrolidine‑1‑carboxylate (1.0 eq) in methanol/tetrahydrofuran (4:1 v/v) at 25 °C for 4 h to form the Schiff base, which is then reduced in situ with sodium triacetoxyborohydride (1.5 eq) at 0–5 °C. The extent of over‑reduction of the pyrazole ring is a recurring failure mode during scale‑up; when the addition rate of the reducing agent exceeds 0.25 eq/minute, the local temperature spike above 10 °C generates a des‑fluoro impurity that is difficult to purge by silica gel chromatography. To circumvent this, a semi‑continuous work‑up is implemented: the reaction mixture is quenched into aqueous sodium bicarbonate over 15 min at ≤ 5 °C, extracted with ethyl acetate, and the organic layer is passed through a wiped‑film evaporator (SMS VTA, jacket 40 °C, 50 mbar) to furnish the tertiary amine intermediate as a viscous oil. The oil is dissolved in isopropanol and treated with oxalic acid (1.0 eq) to precipitate the oxalate salt, which is recrystallised from ethanol/water (95:5) to 99.6% chemical purity and 99.9% ee. The resulting salt serves as the key penultimate intermediate for a selective histamine H3 receptor antagonist undergoing phase II clinical trials for narcolepsy. Because the molecule contains a trifluoroethyl group that is susceptible to defluorination under the acidic conditions of gastric fluid simulation, the formulation development group has specified that the free base equivalent of the amine must be assayed at 99.0–101.0% on an anhydrous basis against a reference standard characterised by quantitative NMR, in full compliance with the requirements of ICH Q6A and the corresponding monograph submitted to the European Directorate for the Quality of Medicines (EDQM).